微信公众号

官网二维码

中国癌症防治杂志 ›› 2013, Vol. 5 ›› Issue (4): 315-319.doi: 10.3969/j.issn.1674-5671.2013.04.07

• 临床研究 • 上一篇    下一篇

HER-2及LRP在非小细胞肺癌中的表达及临床意义

  

  1. 辽宁省人民医院病理科
  • 出版日期:2013-12-25 发布日期:2013-12-31
  • 通讯作者: 侯 慧 E-mail:houhui_qq@126.com

Expression and clinical significance of HER-2 and LRP in non-small cell lung cancer

  • Online:2013-12-25 Published:2013-12-31

摘要: 目的 探讨非小细胞肺癌组织中表皮生长因子受体-2(HER-2)和肺耐药蛋白(LRP)的表达及与临床病理特征的关系。方法 应用免疫组织化学(IHC)EnVision二步法,检测70例非小细胞肺癌组织和35例相应癌旁正常肺组织中HER-2和LRP的表达情况,并结合其临床病理特征进行分析。结果 在非小细胞肺癌组织中,HER-2和LRP的阳性表达率分别为31.4%、72.9%,均分别高于癌旁正常肺组织的表达(P<0.05)。HER-2在腺癌中的阳性表达率为46.0%,在鳞癌中为15.2%,两者差异有统计学意义(P<0.05)。HER-2的表达与淋巴结转移、病理分级、临床分期间无明显差异(P>0.05);LRP在腺癌中的阳性表达率为78.4%,在鳞癌中为66.7%(P>0.05)。LRP的表达与淋巴结转移、病理分级及临床分期间的差异有统计学意义(P<0.05)。结论 HER-2、LRP在非小细胞肺癌组织中有不同程度的表达,检测两者有助于该癌化疗药物的选择及预后的判断。

关键词: 肺肿瘤, 非小细胞肺癌, HER-2, LRP, 基因表达, 免疫组织化学法, 预后

Abstract: Objective  To investigate associations between the expression of lung resistance protein(LRP) and human epidermal growth factor receptor 2(HER-2) and the clinico-pathological features of non-small cell lung cancer. Methods The two-step EnVision immunohistochemical method was used to measure the expression of HER-2 and LRP in 70 cases of non-small cell lung cancer tissues, and 35 corresponding adjacent normal lung tissues. Results Expression rates of HER-2 and LRP were significantly higher in cancer tissue (31.4% and 72.9%,respectively) than in adjacent normal lung tissue (P<0.05). The expression rate of HER-2 was significantly higher in adenocarcinoma(46.0%) than in squamous cell carcinoma(15.2%; P<0.05). However,HER-2 expression did not correlate with lymph node metastasis,pathologic classification or clinical staging(P>0.05).The expression rate of LRP was similar in adenocarcinoma and squamous cell carcinoma(78.4 vs 66.7%,P>0.05),and LRP expression correlated with lymph node metastasis, pathologic classification, and clinical staging(P<0.05). Conclusions HER-2 and LRP proteins are expressed to different degrees in non-small cell lung cancer.Assaying for both may be valuable for designing chemotherapy and predicting prognosis in non-small cell lung cancer.
 

Key words: Lung neoplasms, non-small cell lung cancer, HER-2, LRP, Gene expression, Immunohistochemistry, Prognosis